Introduction:
Sunitinib is an oral antiangiogenic drug with anti-Vascularendothelial growth factor (VEGF) properties. It is used to
treat renal cell carcinoma, pancreatic neuroendocrine tumours, and
gastrointestinal stromal tumours (1)Treatment with anti-VEGF antibody
medication improves the survival of patients with colorectal carcinoma
(2, 3) and clear metastatic cell renal cell carcinoma (4).
Sunitinib-induced thrombotic microangiopathy (TMA) is a secondary TMA
caused by sunitinib. Despite the extensive use of sunitinib in patients
with renal cell carcinoma and other malignancies, little is known about
this complication of sunitinib. No clinical trials of sunitinib have
studied this complication in any group of patients.
TMA is characterised by microangiopathic hemolytic anemia (MAHA),
thrombocytopenia, and various organ dysfunction (5). Multiple case
reports of sunitinib-induced TMA have been published(6-11). In this
study, we report another case of sunitinib induced TMA and discuss
clinical and laboratory manifemanifestationis causes and pathogenesis of
the disease.